[
    [
        {
            "time": "2018-01-02",
            "original_text": "Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar",
            "features": {
                "keywords": [
                    "Novartis",
                    "Trial",
                    "Psoriasis",
                    "Cosentyx",
                    "Biosoimilar"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rova-T",
                    "Label Expansion",
                    "Blockbuster Drug"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Analysts’ Recommendations for Incyte in January 2018",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "Incyte"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Incyte in January 2018",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2018",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Ex-Dividend",
                    "Date",
                    "Scheduled"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2018",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus",
            "features": {
                "keywords": [
                    "Biotech",
                    "Stock",
                    "Roundup",
                    "Celgene",
                    "Acquire",
                    "Impact",
                    "J.P. Morgan",
                    "Healthcare",
                    "Conference"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rova-T",
                    "Treatment",
                    "Small Cell Lung Cancer"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Imbruvica",
                    "Foundation Therapy",
                    "Hematologic Oncology"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)",
            "features": {
                "keywords": [
                    "Better Stock",
                    "AbbVie",
                    "Johnson & Johnson"
                ],
                "sentiment_score": 0.55,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ)",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "AbbVie’s Rova-T: Solid Growth Driver for the Future?",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rova-T",
                    "Growth Driver",
                    "Future"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie’s Rova-T: Solid Growth Driver for the Future?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "AbbVie’s Position in the Growing Oncology Market in 2018",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Position",
                    "Oncology Market",
                    "2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie’s Position in the Growing Oncology Market in 2018",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018",
            "features": {
                "keywords": [
                    "Ex-Dividend",
                    "Alert",
                    "AbbVie",
                    "Dividend",
                    "Raised"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again",
            "features": {
                "keywords": [
                    "LPCN",
                    "FDA",
                    "Panel Vote",
                    "APHB",
                    "Slumps",
                    "BGNE",
                    "$100"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "Breakthrough",
                    "Therapy",
                    "Designation"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie's Upadacitinib Gains Breakthrough Therapy Designation",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]